Ballaz S, Bourin M
Curr Neuropharmacol. 2020; 19(7):925-938.
PMID: 33185164
PMC: 8686311.
DOI: 10.2174/1570159X18666201113145143.
Ballaz S, Bourin M, Akil H, Watson S
Prog Neuropsychopharmacol Biol Psychiatry. 2019; 96:109761.
PMID: 31526831
PMC: 6935156.
DOI: 10.1016/j.pnpbp.2019.109761.
Ballaz S, Perez J, Waselus M, Akil H, Watson S
Neuroscience. 2013; 255:68-75.
PMID: 24121132
PMC: 3855030.
DOI: 10.1016/j.neuroscience.2013.09.063.
Steimer T
Dialogues Clin Neurosci. 2011; 4(3):231-49.
PMID: 22033741
PMC: 3181681.
Liu Y, Yang N, Zuo P
Cell Mol Neurobiol. 2010; 30(7):1035-47.
PMID: 20532976
PMC: 11498782.
DOI: 10.1007/s10571-010-9534-8.
Wiring and volume transmission in rat amygdala. Implications for fear and anxiety.
Perez de la Mora M, Jacobsen K, Crespo-Ramirez M, Flores-Gracia C, Fuxe K
Neurochem Res. 2008; 33(8):1618-33.
PMID: 18473172
DOI: 10.1007/s11064-008-9722-9.
Impact of state and trait anxiety on the panic response to CCK-4.
Eser D, Wenninger S, Baghai T, Schule C, Rupprecht R
J Neural Transm (Vienna). 2008; 115(6):917-20.
PMID: 18414777
DOI: 10.1007/s00702-008-0047-2.
The CCK-system underpins novelty-seeking behavior in the rat: gene expression and pharmacological analyses.
Ballaz S, Akil H, Watson S
Neuropeptides. 2008; 42(3):245-53.
PMID: 18410964
PMC: 2706500.
DOI: 10.1016/j.npep.2008.03.001.
Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.
Nordquist R, Steckler T, Wettstein J, Mackie C, Spooren W
Psychopharmacology (Berl). 2008; 199(3):389-402.
PMID: 18322676
DOI: 10.1007/s00213-008-1096-9.
Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers.
Eser D, Leicht G, Lutz J, Wenninger S, Kirsch V, Schule C
Hum Brain Mapp. 2007; 30(2):511-22.
PMID: 18095276
PMC: 6870703.
DOI: 10.1002/hbm.20522.
Delayed increase in LDL cholesterol following pentagastrin-induced panic attacks.
Perez-Parada J, Jhangri G, Lara N, Chrapko W, Castillo Abadia M, Gil L
Psychopharmacology (Berl). 2007; 193(3):333-40.
PMID: 17450352
DOI: 10.1007/s00213-007-0759-2.
Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
Eser D, Schule C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M
Psychopharmacology (Berl). 2007; 192(4):479-87.
PMID: 17318504
DOI: 10.1007/s00213-007-0738-7.
Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.
Chen Q, Nakajima A, Meacham C, Tang Y
Proc Natl Acad Sci U S A. 2006; 103(10):3881-6.
PMID: 16537459
PMC: 1383652.
DOI: 10.1073/pnas.0505407103.
Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies.
Andre J, Zeau B, Pohl M, Cesselin F, Benoliel J, Becker C
J Neurosci. 2005; 25(35):7896-904.
PMID: 16135746
PMC: 6725462.
DOI: 10.1523/JNEUROSCI.0743-05.2005.
New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454.
Bellier B, Crete D, Million M, Beslot F, Bado A, Garbay C
Naunyn Schmiedebergs Arch Pharmacol. 2004; 370(5):404-13.
PMID: 15480577
DOI: 10.1007/s00210-004-0969-7.
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.
Rotzinger S, Vaccarino F
J Psychiatry Neurosci. 2003; 28(3):171-81.
PMID: 12790157
PMC: 161741.
cDNA microarray analysis of gene expression in anxious PVG and SD rats after cat-freezing test.
Wang H, Zhu Y, Wong P, Farook J, Teo A, Lee L
Exp Brain Res. 2003; 149(4):413-21.
PMID: 12677321
DOI: 10.1007/s00221-002-1369-1.
5-HT3 receptors mediate serotonergic fast synaptic excitation of neocortical vasoactive intestinal peptide/cholecystokinin interneurons.
Ferezou I, Cauli B, Hill E, Rossier J, Hamel E, Lambolez B
J Neurosci. 2002; 22(17):7389-97.
PMID: 12196560
PMC: 6757992.
Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice.
Holmes A, Yang R, Crawley J
J Mol Neurosci. 2002; 18(1-2):151-65.
PMID: 11931346
DOI: 10.1385/JMN:18:1-2:151.
Response to pentagastrin after acute phenylalanine and tyrosine depletion in healthy men: a pilot study.
Coupland N, Zedkova L, Sanghera G, Leyton M, Le Melledo J
J Psychiatry Neurosci. 2001; 26(3):247-51.
PMID: 11394194
PMC: 1408307.